ALK and non-small cell lung carcinoma: However, the results of the ATLANTIC study (n = 444) demonstrated that high PD‐L1‐expressing (≥ 25%) and EGFR/ALK mutation‐positive advanced NSCLC patients might have greater benefit from ICI treatment with durable efficacy and a promising effect on OS than patients with PD‐L1 expression <25% and EGFR/ALK mutation (median OS: 13.3 vs. 9.9 months).46